Some of these proteins are exclusively expressed on LSCs or display a higher expression level as compared to normal CD34+CD38- HSCs representing potential targets for immunotherapy approaches (e.g., BiTEs or CAR-T cells) in AML treatment [188]. The gene discussed is CD38; the disease is acute myeloid leukemia.